Modern Biopharmaceuticals Design Development And Optimization 4Vol Set Cd (Hb 2005)

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.

With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.

Dr. Jorg Knablein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).

AWARDS:
Riedel-de Haen-Stiftung
Government / Ministry of Science
Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)
Winner of the McKinsey business plan contest